Funding Alert Health tech

Berlin’s Oviva raises €200M to bring AI obesity care to more European health systems

• ByStartupStory     |    January 23, 2026

With 200 million European adults battling obesity and chronic illnesses like diabetes and hypertension, health systems are overwhelmed. Oviva tackles this gap with fully reimbursed digital therapy programmes for weight-related and chronic conditions, integrated into public systems in Germany, the UK, and Switzerland.

Its platform combines a certified medical app with remote multidisciplinary care teams, enabling patients to access evidence-based lifestyle and behavioural interventions without long delays or geographic barriers. To date, more than 1 million patients across Europe have been treated using Oviva’s digital health solutions.

Today, the startup has raised €200M Series D, split between new cash and secondary sales, from Kinnevik, Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen, Norrsken VC, and existing backer Sofina.

Putting real care in patients’ pockets

Kai Eberhardt (CEO) and Manuel Baumann (CTO) launched Oviva in 2014 to become Europe’s backbone for digital chronic care, blending tech with human expertise. ​

Oviva’s platform combines a medical-device-certified app with multidisciplinary clinical teams (such as dietitians and specialists) to deliver structured, evidence-based programmes at scale. AI is embedded across the platform to tailor treatment pathways, support clinicians in their daily work, and safeguard consistent quality even as patient volumes grow.

Standouts include full reimbursement (DiGA in Germany, NHS tie-ups in the UK, Swiss system integration), strong clinical evidence from 90+ studies demonstrating lasting results, and a human-AI mix that aligns with real health systems.​

Unlike Kry/Livi, HelloBetter, Omada Health, or Noom, Oviva focuses on reimbursement footprint, weight-related and metabolic conditions, and European health-system integration.​

What’s next?

With the new €200M round, Oviva plans to broaden its digital programmes into more chronic indications, including hypertension and type 2 diabetes, to better prevent and manage comorbidities.

Follow Startup Story